Revenue FY2025
$44.33B
Net Income
$6.52B
EPS (Basic)
$3.73
Net Margin
14.7%
ROE
12.5%
Total Equity
$52.13B
Shares Out
1.74B
ABBOTT LABORATORIES — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2007–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.
Revenue & Net Income (10Y)
Margin Trends
Investor Ownership · 18 funds in our universe
FundPosition Value% of AUMQoQ ChgWeight
Southeastern Asset Management
Mason Hawkins
$0.08B
2.1%
NEW
Jensen Investment Management
Jensen
$0.08B
1.2%
(40.4%)
Mairs & Power
Mairs & Power
$0.07B
0.6%
+1.1%
Capital Research Global Investors
Capital Research Global Investors
$3.35B
0.5%
(25.8%)
Holocene Advisors
Holocene Advisors
$0.23B
0.4%
+214.9%
Matrix Asset Advisors
David Katz
$0.00B
0.3%
NEW
Adage Capital Management
Adage Capital Management
$0.21B
0.3%
+36.6%
Suvretta Capital Management
Suvretta Capital Management
$0.01B
0.1%
—
Renaissance Technologies
Renaissance Technologies
$0.06B
0.1%
(44.6%)
Soros Fund Management
Soros family office
$0.00B
0.1%
—
Alps Advisors
Alps Advisors
$0.02B
0.0%
+6.0%
Zevenbergen Capital Investments
Zevenbergen Capital Investments
$0.00B
0.0%
(12.5%)
Fairview Capital Investment Management
Fairview Capital Investment Management
$0.00B
0.0%
(27.0%)
Gardner Russo & Quinn
Thomas Russo
$0.00B
0.0%
—
Bridgewater Associates
Bridgewater Associates
$0.01B
0.0%
(48.9%)
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management
$0.00B
0.0%
—
Polen Capital Management
Polen
$0.00B
0.0%
(79.1%)
Dodge & Cox
Dodge & Cox
$0.00B
0.0%
—
Insider Transactions
Reading stored insider transactions…